Navidea Biopharmaceuticals, Inc.
NAVB · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -87.6% | -41.9% | 3,337.6% | – |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | -259.4% | 62.6% | 99.9% | 75% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -21,298.7% | -2,164.9% | -1,162.9% | -40,641.7% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -23,117.6% | -2,207.1% | -1,171.8% | -41,120.9% |
| EPS Diluted | -0.56 | -0.4 | -0.48 | -0.76 |
| % Growth | -40% | 16.7% | 36.8% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |